Omeros’ proprietary DTLacO technology is an ex vivo antibody discovery platform that pairs an engineered chicken B-cell line with antibody selection strategies and also has antibody repertoire from which specific antibodies are selected basing on the therapy requirement.
Omeros chairman and chief executive officer Gregory Demopulos said Omeros DTLacO platform can generate antibodies that target a wide range of diseases, including multiple types of cancer.
”With respect to our orphan GPCR program, the DTLacO platform nicely complements our proprietary cellular redistribution assay that, to date, has identified small molecules that functionally interact with 42 orphan GPCRs,” Demopulos added.
Demopulos further said DTLacO platform provides different approach to discover and develop drugs for the receptors that are resistive to high-throughput CRA approach.